Papers/PMID:27560482
Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials.
PloS one2016The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
resveratrol — increases total cholesterol (TC)
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.Finding“As shown in, total cholesterol (MD = 0.49, 95% CI: 0.18, 0.80, P < 0.05) and LDL (MD = 0.47, 95% CI: 0.21, 0.74, P < 0.05) levels were significantly higher in subjects supplemented with resveratrol than control subjects.”
Quoted verbatim from Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials.. - Study
- meta-analysis
- Dose
- 500-3000 mg/day resveratrol
- Population
- Adults with non-alcoholic fatty liver disease; total cholesterol pooled from 3 of the 4 placebo-controlled trials
Effect 0.49 mean difference, 95% CI 0.18 to 0.8
Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials.2016PMID:27560482Permalink